Compare AMWL & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMWL | MXCT |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.8M | 81.6M |
| IPO Year | 2020 | 2021 |
| Metric | AMWL | MXCT |
|---|---|---|
| Price | $5.55 | $0.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $7.42 | $5.50 |
| AVG Volume (30 Days) | 56.2K | ★ 982.6K |
| Earning Date | 04-30-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | $18.61 |
| Revenue Next Year | $4.24 | $22.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.71 | $0.64 |
| 52 Week High | $9.15 | $2.96 |
| Indicator | AMWL | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 38.93 |
| Support Level | $4.48 | $0.64 |
| Resistance Level | $5.81 | $0.87 |
| Average True Range (ATR) | 0.34 | 0.06 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 26.90 | 28.02 |
American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.